QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
QQQ   284.45 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.85 (-4.18%)
BABA   92.35 (-1.93%)
AMD   69.64 (-1.18%)
T   19.20 (+0.42%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.23 (+0.84%)
GE   82.26 (-1.64%)
DIS   94.13 (+1.71%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.90 (+0.23%)
NFLX   325.08 (+4.78%)
NYSE:ENZ

Enzo Biochem - ENZ Stock Forecast, Price & News

$1.87
-0.01 (-0.53%)
(As of 12/9/2022 01:10 PM ET)
Add
Compare
Today's Range
$1.85
$1.88
50-Day Range
$1.78
$2.42
52-Week Range
$1.74
$3.70
Volume
140 shs
Average Volume
39,208 shs
Market Capitalization
$91.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Enzo Biochem MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Enzo Biochem in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$197,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

Medical Sector

972nd out of 1,022 stocks

Medical Laboratories Industry

24th out of 25 stocks

ENZ stock logo

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.

Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings
10/15/2019
Today
12/09/2022
Next Earnings (Estimated)
12/21/2022
Fiscal Year End
7/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
451
Year Founded
N/A

Profitability

Net Income
$-18,260,000.00
Pretax Margin
-17.06%

Debt

Sales & Book Value

Annual Sales
$107.07 million
Book Value
$1.12 per share

Miscellaneous

Free Float
40,243,000
Market Cap
$91.11 million
Optionable
Optionable
Beta
0.78

Key Executives

  • Dr. Elazar Rabbani Ph.D. (Age 79)
    Co-Founder & Director
    Comp: $830.9k
  • Dr. Dieter Schapfel M.D. (Age 59)
    Chief Medical Director of Enzo Clinical Labs
    Comp: $404.03k
  • Mr. Hamid Erfanian (Age 52)
    CEO & Director
  • Mr. David A. Bench
    CFO, Sr. VP, Treasurer & Corp. Sec.
  • Ms. Kara Cannon (Age 53)
    Chief Operating Officer
  • Mr. Matthew Kupferberg
    Gen. Counsel
  • Mr. Bruce A. Dey (Age 64)
    VP of Sales & Marketing - Enzo Clinical Labs













ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2022?

Enzo Biochem's stock was trading at $3.21 at the beginning of the year. Since then, ENZ stock has decreased by 41.4% and is now trading at $1.88.
View the best growth stocks for 2022 here
.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest in October. As of October 31st, there was short interest totaling 403,100 shares, an increase of 5.9% from the October 15th total of 380,600 shares. Based on an average trading volume of 47,300 shares, the short-interest ratio is currently 8.5 days. Currently, 1.1% of the shares of the company are sold short.
View Enzo Biochem's Short Interest
.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 21st 2022.
View our ENZ earnings forecast
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The medical research company earned $20.92 million during the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 21.26% and a negative net margin of 17.06%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.97%), Dimensional Fund Advisors LP (3.27%), BlackRock Inc. (3.01%), Group One Trading L.P. (0.00%), Citadel Advisors LLC (0.00%) and Tower Research Capital LLC TRC (0.05%). Insiders that own company stock include Bradley Louis Radoff, David Bench, Discovery Fund Lp Harbert, Hamid Erfanian, Kara Cannon and Peter J Iv Clemens.
View institutional ownership trends
.

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $1.88.

How much money does Enzo Biochem make?

Enzo Biochem (NYSE:ENZ) has a market capitalization of $91.59 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Enzo Biochem have?

The company employs 451 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 12/9/2022 by MarketBeat.com Staff